Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial

Truist Financial began coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note issued to investors on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $51.00 price objective on the stock.

AAPG has been the subject of several other reports. Piper Sandler assumed coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price objective for the company. BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $49.67.

Ascentage Pharma Group International Price Performance

Shares of NASDAQ AAPG opened at $32.03 on Monday. The business has a 50-day moving average price of $35.48 and a 200 day moving average price of $36.06. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. Ascentage Pharma Group International has a 52-week low of $16.50 and a 52-week high of $48.45.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several large investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International in the 3rd quarter valued at $383,000. XY Capital Ltd lifted its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares during the period. UBS Group AG boosted its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International during the third quarter worth about $204,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International during the third quarter worth about $96,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.